Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Dr. Axel Paeger, MD, MBA, MBI to its Board of Directors.

GlobeNewsWire • Feb 23, 2026

Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?

Here is how Anavex Life Sciences (AVXL) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

Zacks Investment Research • Feb 12, 2026

Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know

Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Feb 12, 2026

Anavex Life Sciences Corp. (AVXL) Q1 2026 Earnings Call Transcript

Anavex Life Sciences Corp. (AVXL) Q1 2026 Earnings Call Transcript

Seeking Alpha • Feb 9, 2026

Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

Company to host a  webcast today at 8:30 am Eastern Time

GlobeNewsWire • Feb 9, 2026

Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026

Webcast and Conference Call To be Held Monday, February 9, 2026, 8:30 am ET Webcast and Conference Call To be Held Monday, February 9, 2026, 8:30 am ET

GlobeNewsWire • Feb 3, 2026

Anavex Life Sciences Corp. (AVXL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Anavex Life Sciences Corp. (AVXL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced its participation as a key industry partner in ACCESS-AD, a major new European initiative designed to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer's disease (AD) across real-world clinical settings. The five year program is funded by the European Commission's Innovative Health Initiative (IHI) and unites leading academic centers, technology developers, industry innovators and patient organizations to strengthen equitable access to timely and effective AD care.

GlobeNewsWire • Jan 13, 2026

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm

NEWTOWN, Pa., Jan. 8, 2026 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Anavex Life Sciences Corp. ("Anavex") (NASDAQ: AVXL), resulting from allegations of providing potentially misleading business information to the investing public.

PRNewsWire • Jan 9, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Jan 8, 2026